Profil
Tina Abild Olesen is currently Vice Chairman at World Diabetes Foundation, Managing Director at Novo Nordisk Pharma GmbH, and Director at Embla Medical hf since 2024.
Formerly, Ms. Olesen was Senior Vice President-Global Diabetes Franchise at Novo Nordisk A from 2022 to 2025.
Education includes graduate and MBA degrees from Copenhagen Business School.
Postes actifs de Tina Olesen
| Sociétés | Poste | Début |
|---|---|---|
| EMBLA MEDICAL HF. | Directeur/Membre du Conseil | 01/03/2024 |
Novo Nordisk Pharma GmbH
Novo Nordisk Pharma GmbH Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Directeur Général | - |
World Diabetes Foundation
World Diabetes Foundation Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment | Directeur/Membre du Conseil | - |
Anciens postes connus de Tina Olesen
| Sociétés | Poste | Fin |
|---|---|---|
| NOVO NORDISK A/S | Corporate Officer/Principal | 01/08/2025 |
Formation de Tina Olesen
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Novo Nordisk A/S
Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
Novo Nordisk Pharma GmbH
Novo Nordisk Pharma GmbH Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Health Technology |
Embla Medical hf
Embla Medical hf Medical SpecialtiesHealth Technology Provides non-invasive orthopedic products and support services | Health Technology |
Copenhagen Business School
Copenhagen Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
World Diabetes Foundation
World Diabetes Foundation Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment | Miscellaneous |
















